The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,318.00
Bid: 12,288.00
Ask: 12,292.00
Change: -52.00 (-0.42%)
Spread: 4.00 (0.033%)
Open: 12,326.00
High: 12,428.00
Low: 12,260.00
Prev. Close: 12,370.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-EU expects to vaccinate majority by end-June - Bloomberg

Tue, 06th Apr 2021 10:33

(Adds details)

April 6 (Reuters) - Most European Union states will have
enough COVID-19 vaccines to immunize the majority of their
people by the end of June, Bloomberg News reported on Tuesday,
citing an internal memo.

Germany, France, Italy, Spain and the Netherlands will be in
a position to fully inoculate more than 55% of their populations
by June end, the report https://www.bloomberg.com/news/articles/2021-04-06/eu-will-near-virus-immunity-by-end-june-internal-memo-shows?sref=SCAzRb9t
added, citing projections in the memo by the EU executive, the
European Commission.

The numbers confirm public estimates of vaccines the
27-nation bloc expects to receive in the second quarter.

The Commission has repeatedly said the EU, with a population
of nearly 450 million, is to receive about 360 million doses by
the end of June in addition to about 100 million already
shipped.

That would be sufficient to meet its target of vaccinating
at least 70% of the bloc's adult population by the summer.

The bloc expects to receive in the April-June period 55
million doses of the single-dose vaccine developed by Johnson &
Johnson, and another 300 million of two-dose shots from
BioNTech-Pfizer , AstraZeneca and
Moderna.

It is however unclear whether all expected doses will be
delivered in line with timetables. The EU received about half of
the expected doses in the first quarter because AstraZeneca made
major cuts in its supplies to the EU then.

The new estimates already factor in a further major cut in
AstraZeneca supplies in the second quarter.

The EU has coordinated the purchase of vaccines with EU
governments but has no power on vaccination plans, which are run
by EU states.

Roll-outs depend on supplies but also on vaccination
programmes, which have often been hampered in EU states because
of safety and effectiveness concerns over the AstraZeneca
vaccine.

The vaccine roll-out picked up in the bloc at the end of
March after a slow start.
(Reporting by Aakriti Bhalla in Bengaluru; additional reporting
by Francesco Guarascio in Brussels; Editing by Andrew Cawthorne
and Giles Elgood)

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.